Table 2 Most common treatment related adverse events with grade 1 or above
Events, n (%) | 60 mg (n = 12) | 200 mg (n = 12) | 400 mg (n = 12) | Total (n = 36) |
|---|---|---|---|---|
All TRAE | 7 (58.3) | 10 (83.3) | 12 (100.0) | 29 (80.6) |
TRAEs observed in ≥5% of patients | ||||
RCCEP | 3 (25) | 8 (66.7) | 12 (100) | 23 (63.9) |
Hypothyroidism | 4 (33.3) | 4 (33.3) | 1 (8.3) | 9 (25.0) |
Abnormal hepatic function | 1 (8.3) | 1 (8.3) | 4 (33.3) | 6 (16.7) |
Rash | 2 (16.7) | 2 (16.7) | 1 (8.3) | 5 (13.9) |
Hypertriglyceridemia | 2 (16.7) | 1 (8.3) | 2 (16.7) | 5 (13.9) |
Pyrexia | 1 (8.3) | 2 (16.7) | 1 (8.3) | 4 (11.1) |
Hyperthyroidism | 0 | 2 (16.7) | 1 (8.3) | 3 (8.3) |
Vitiligo | 0 | 2 (16.7) | 0 | 2 (5.6) |
Fatigue | 0 | 1 (8.3) | 1 (8.3) | 2 (5.6) |
Increased γ-glutamyltransferase | 2 (16.7) | 0 | 1 (8.3) | 3 (8.3) |